结直肠癌中HSP60和HSP27表达的免疫组织化学研究

目的1观察热休克蛋白60和热休克蛋白27在结直肠癌中的表达及意义。方法：收集结直肠癌80例,其中淋巴结转移40例（转移组）,无淋巴结转移40例（无转移组）;另外,在结直肠癌80例中,有结直肠腺瘤（腺瘤组）以及距肿块15cm以上的正常肠粘膜（对照组）各40例。应用免疫组织化学SP法检测组织中蛋白的表达。结果：HSP60的表达主要定位在癌细胞胞浆,在对照组、腺瘤组、非转移组、转移组中的表达阳性率分别为25％、30％、57．5％、90％,组间比较发现,对照组与转移组、腺瘤组与转移组、转移组与非转移组（x^2=10．912,P〈0．001）的HSP60阳性表达率存在统计学差异;而对照组与腺瘤和非转移组间以及腺瘤与非转移组间无统计学差异。HSP27的表达主要定位在癌细胞的胞浆,在对照组、腺瘤组、非转移组、转移组的表达阳性率分别为5％,35％,50％,90％,组间比较发现,对照组分别与无淋巴结转移组、淋巴结转移组;腺瘤组分别与转移组;非转移组与转移组间存在统计学差异,腺瘤与非转移组间无统计学差异。HSP60和HSP27表达间无统计学相关。结论：HSP27表达可能与结直肠癌发生和转移相关。而HSP60的表达可能在结直肠癌转移中具有重要意义。     

基于MALDI-TOF MS技术子宫内膜癌血清学诊断模型的建立及验证

目的:通过基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)技术建立子宫内膜癌(EC)血清学诊断模型。方法:收集53例EC初诊患者和37例子宫内膜良性病变患者血清,按照2∶1随机分为训练组60例(EC患者35例,良性病变患者25例)和验证组30例(EC患者18例,良性病变患者12例);通过弱阳离子交换磁珠(MB-WCX)提取血清蛋白,经MALDI-TOF MS筛选差异蛋白。根据训练组中差异蛋白建立诊断模型,用验证组验证诊断模型的敏感性、特异性及诊断效率。结果:筛选出47个差异蛋白峰(P0.05),联合ROC曲线分析筛出AUC0.80的差异峰14个,其中在EC组表达上调的蛋白有7个;m/z分别为1779.63和1866.76 Da的2个蛋白峰差异性最显著,AUC分别为0.935和0.969,且EC组的平均峰值强度和峰下面积明显低于良性病变组。以上述2个蛋白建立诊断模型,经验证其敏感性为88.89%,特异性为91.67%,诊断效率为90%。结论:利用MALDI-TOF MS技术建立的EC血清学诊断模型有较高的敏感性和特异性,有望用于EC的早期筛查和辅助诊断。提示蛋白峰m/z 1779.63和1866.76 Da可能成为EC的潜在肿瘤标志物。     

高危结直肠腺瘤的危险因素及风险预测模型的构建与验证

摘要 目的：探讨高危结直肠腺瘤的影响因素,构建风险预测模型并验证。方法：回顾性分析2021年1月至2021年12月期间在江苏大学附属人民医院进行诊疗的1408例结直肠腺瘤患者的资料,根据病理特征分为高危结直肠腺瘤组（759例）和非高危结直肠腺瘤组（649例）。采用Logistic回归分析筛选高危结直肠腺瘤的独立危险因素并建立风险预测模型,并验证预测模型的应用效能。结果：Logistic回归分析结果显示,病灶部位为直肠、高血压、高脂血症、年龄≥53岁、吸烟是高危结直肠腺瘤的独立危险因素（P＜0.05）。基于以上因素建立预测高危结直肠腺瘤风险的列线图模型,经Hosmer-Lemeshow检验和受试者工作特征曲线（ROC）分析显示,该风险预测模型具有较好的拟合度和预测效能,可以用于高危腺瘤的风险预测。结论：病灶部位为直肠、高血压、高脂血症、年龄≥53岁、吸烟是高危结直肠腺瘤的独立危险因素,临床医生可尽早对高危患者进行预防性干预以减缓高危腺瘤的发生。     

MXRA5在结直肠癌中的表达及其意义

目的:在我们的前期实验中,我们运用质谱技术研究新鲜培养的结直肠癌和对应的正常黏膜蛋白组学差异时发现基质重建相关蛋白5(MXRA5)在两者之间的表达有明显的差异,而目前并没有关于MXRA5是否可以作为结直肠癌肿瘤标志物的研究;本实验的目的是探索MXRA5在结直肠癌中的表达情况以及其临床意义.方法:运用免疫组化和实时定量PCR技术,对MXRA5在结直肠中的表达情况进行检测,并分析其与临床病理特征的关系.结果:MXRA5在结直肠正常组织、腺瘤和肿瘤中的免疫评分有明显差异(P＜0.05),而且MXRA5的阳性表达与肿瘤的分期和大网膜转移明显相关.基因水平MXRA5的表达没有发现明显差异.结论:我们的研究结果证实了MXRA5在肠癌组织中存在异常表达,并且可能是结直肠癌早期诊断或者大网膜转移的肿瘤标志物.     

SELDI-TOF-MS筛选慢性阻塞性肺疾病血清标志蛋白的初步研究

目的:利用表面增强激光解吸电离飞行时间质谱技术(SELDI-TOF-MS)筛选慢性阻塞性肺疾病(COPD)血清特异标志物。方法:应用SELDI-TOF-MS技术检测30例COPD稳定期患者和30例健康对照者血清蛋白指纹图谱,采用Biomarker pattern软件进行分析,建立COPD的诊断模型。结果:COPD患者血清蛋白图谱与对照组相比,在相对分子质量2000-15 000范围内共检测到75个蛋白峰,发现19个有统计学差异的蛋白峰(P0.05)。通过对COPD组与对照组间的数据作进一步分析,经BPS软件分析,建立质荷比(M/Z)3 167、4 645的差异蛋白组成的诊断模型,其诊断敏感度为96.67%,特异度为96.67%。结论:SELDI-TOF-MS技术是一种快速、简单易行、用量少和高通量的分析方法。能直接筛选出COPD血清中特异表达标志物,用特异表达标志物建立的诊断模型能有效区分COPD患者与健康对照者,有望成为COPD诊断的辅助指标。     

结直肠癌PTEN基因表达及与p-ERK相关性研究

目的 研究结直肠癌中的PTEN、p-ERK蛋白的表达及相互关系,初步探讨它们在结直肠癌的发生发展中的生物学意义.方法 应用免疫组织化学染色快捷法,检测40例结直肠癌组织、18例结直肠腺瘤、13例结直肠正常黏膜中PTEN蛋白、和p-ERK蛋白的表达情况,比较PTEN蛋白表达与临床病理指标的关系,及其与p-ERK蛋白表达的相关性.结果 1.结直肠癌癌组织PTEN蛋白表达的阳性率(57.5％)明显弱于腺瘤(72.2％)及正常组织(100％),组间比较差异有显著性(P＜0.05),其表达水平与结直肠癌的分化程度、淋巴结转移、浸润深度、Dukes分期有关,与患者的性别、年龄,肿瘤大小及位置无关(P＞0.05)2.结直肠癌组织p-ERK蛋白表达的阳性率(72.5％)明显高于正常结直肠黏膜组(0.00％)及腺瘤组(66.6％),组间比较差异有显著性(P＜0.01),其表达随结直肠癌侵润深度增加、淋巴结转移、Duke分期的进展而增高.3.PTEN蛋白表达强度与p-ERK蛋白表达强度之间呈负相关(r=-0.452,P＜0.05).结论 提示抑癌基因PTEN的表达与结直肠癌生物学行为密切相关;在结直肠癌发生、发展过程中,可能由于PTEN蛋白的低表达或失表达不能有效抑制ERK磷酸化,使细胞发生癌变,并促进癌变细胞的浸润、转移.     

IGF-Ⅱ、IGF-1R、IGFBP-3在结直肠癌中的表达及诊断价值研究

目的：探讨结直肠癌中IGF-Ⅱ、IGF-1R以及IGFBP-3等的阳性表达及诊断价值。方法：收集我院45例结直肠癌、33例炎性息肉、40例腺瘤以及35例正常肠粘膜组织予以免疫组织化学SP法进行IGF—Ⅱ、IGF—1R以及IGFBP-3检测,并统计结直肠腺瘤不同组织类型和结直肠癌不同Dukes分期的阳性表达差异。结果：结直肠癌组织中IGF—Ⅱ、IGF—1R以及IGFBP-3表达均呈高阳性率,并且显著高于其他3组（P〈0．05）。结直肠腺瘤管状、混合型、绒毛状等不同组织类型IGF-Ⅱ、IGF—1R以及IGFBP-3表达阳性率呈逐渐增高趋势,绒毛状腺瘤显著高于其他两型（P〈0．05）。45例结直肠癌中,Dukes分期A、B两期显著低于C期和D期,比较差异具有显著性（P〈0．05）。结论：IGF—Ⅱ、IGF-1R以及IGFBP-3可能在结直肠腺瘤发生、发展及进展为结直肠癌的过程中起一定作用,对结直肠癌早期诊断具有一定价值。     

PDGF-D、MPO与CD15在大肠癌中的表达及临床相关性研究

目的：探讨血小板源性生长因子D（PDGF-D）、髓过氧化物酶（MPO）YL粒细胞相关抗原（CD15）在大肠癌组织中的表达及其与临床特征之间的关系。方法：采用免疫组化染色方法检测88例大肠癌组织、72例大肠腺瘤组织及50例正常大肠粘膜组织中PDGF-D、MPO及CD15的表达情况。结果：PDGF—D、MPO、CD15在大肠癌组织中的阳性表达率分别为85．23％、63．64％、61．36％。PDGF—D、MPO在正常组、大肠腺瘤组和大肠癌组三者之间的表达均有显著性差异（P〈0．05）。CD15在正常组、大肠腺瘤组中的阳性表达率与大肠癌组中的阳性表达率有显著性差异（P〈0．05）,但在正常组与大肠腺瘤组中的阳性表达率无显著性差异（P〉0．05）。PDGF—D、MPO、CD15的表达在有淋巴结转移组织中的阳性率分别为92_31％、75．00％,73．08％;在无淋巴结转移组织中的阳性率分别为75．00％、52．78％,47．22％,三者在有无淋巴结转移组织中的阳性率均有显著性差异（P〈0．05）。PDGF．D、MPO、CD15在大肠癌中的表达与性别、年龄及组织分化程度均无相关（P〉0．05）。经Spearman相关性分析,PDGF—D及MPO在大肠癌的表达具有相关性（P〈O．05）。大肠癌中CD15与PDGF—D、MPO的表达无明显相关性（P〉0．05）：结论：PDGF—D、MPO与CDl5在大肠癌中的高表达,提示均参与了大肠癌的发生发展,可作为大肠癌恶性程度和侵袭转移的分子生物学标志物。     

宫颈腺癌发生相关蛋白的蛋白质组学初步研究

目的：为了研究宫颈腺癌和正常宫颈组织的差异表达蛋白,为宫颈腺癌的发生和早期诊断提供有意义的生物标志物。方法：以正常宫颈组织和宫颈腺癌组织为研究对象,提取组织总蛋白,依次进行二维凝胶电泳,凝胶图象分析,基质辅助激光解吸附／离子化飞行时间质谱及生物信息学分析。Western Blot方法验证部分蛋白表达情况。结果：建立了宫颈腺癌和正常宫颈组织的二维电泳图谱,进行质谱和生物信息学分析比较鉴定宫颈腺癌和正常宫颈组织差异表达蛋白7个,与正常宫颈组织比较,宫颈腺癌表达降低的蛋白有3个,包括抑制素（inhibin-beta）,PTEN,乳铁蛋白（lactoferrin）;宫颈腺癌表达升高的蛋白有4个,包括谷胱甘肽S-转移酶（GSTT1＊0）,Homeodomain—interacting protein kinase2（HIPK2）,CD44v5,galectin-7。Western Blot方法检测结果显示inhibin-beta和PTEN在宫颈腺癌中表达变化情况与蛋白质组学结果一致。结论：宫颈腺癌和正常宫颈组织存在差异表达蛋白,这些差异表达蛋白可能是宫颈腺癌发生相关蛋白,可能作为宫颈腺癌早期诊断的标志物。     

基于蛋白组学的脓毒症补体凝血级联通路及标志物KLKB1研究

摘要 目的：通过蛋白质组学方法鉴定脓毒症关键通路及诊断标志物。方法：选取2019年1月至12月西南医科大学附属医院急诊科收治的56例脓毒症患者（脓毒症组）,另取同期50名健康体检志愿者（对照组）。采用随机抽样法分别选取两组中12名脓毒症患者和8名健康体检志愿者,利用非数据依赖模式（DIA）进行血清蛋白数据采集,将数据上传至iDEP在线平台分析脓毒症患者外周血中差异表达蛋白,进一步对这些差异蛋白进行生物信息学分析,包括主成分分析（PCA）、基因本体富集分析（GO）、通路富集分析和蛋白-蛋白相互作用网络（PPI）分析,进而筛选出脓毒症关键蛋白。采用酶联免疫吸附试验（ELISA）对脓毒症组、对照组进行关键蛋白表达验证分析。采用受试者工作特征（ROC）曲线分析关键蛋白对脓毒症的诊断效能。结果：蛋白质组学分析共鉴定出690个蛋白,筛选出171个差异表达蛋白（DEPs）,其中39个蛋白显著下调,132个蛋白显著上调。DEPs富集的核心通路为补体和凝血级联通路。该条通路中的血清激肽释放酶 1（KLKB1）在脓毒症组的表达水平为（121.80±55.63 ng/mL）,显著高于对照组的（68.30±57.11 ng/mL）,差异具有统计学意义（t=4.881,P=0.000）。根据ELISA结果进行脓毒症诊断ROC曲线分析得出,KLKB1蛋白诊断脓毒症的 AUC（95%CI）为0.759（0.594～0.923）。结论：补体和凝血级联通路为脓毒症免疫途径的重要通路,KLKB1具有较好的脓毒症诊断特性,可能是脓毒症潜在的诊断生物标志物。     

表面增强激光解吸电离飞行时间质谱技术筛查肺癌血清特异性蛋白质及其临床意义

目的:探讨用表面增强激光解吸电离飞行时间质谱(SELDI-TOF-MS)技术筛查肺癌血清特异性蛋白质的临床意义。方法:应用SELDI-TOF-MS对35例正常对照组、43例治疗前肺癌病人的血清样品进行蛋白质指纹图谱测定,用BioMarker Wizard 3．01及BioMarker Parrern System 5．01分析软件对测得的数据进行处理及建立诊断模型。结果:共检测到251个蛋白质峰,筛选出差异蛋白质峰11个,以质荷比(m/z)分别为M2799_26,M3227_41,M5739_70和M8164_30的4个蛋白质峰为依据组合构建分类决策树模型,分出5个终节点。决策树模型的原始判别总准确率为91．0%(71/78),敏感性为88．4%(38/43),特异性为94．3%(33/35);交叉验证总准确率为85．9%(67/78),敏感性为88．4%(38/43),特异性为82．9%(29/35)。结论:SELDI-TOF-MS在肺癌血清特异性蛋白质的筛选及诊断模型的建立有一定的临床意义。     

Identification of Kininogen-1 as a Serum Biomarker for the Early Detection of Advanced Colorectal Adenoma and Colorectal Cancer

Background

Serum markers represent potential tools for the detection of colorectal cancer (CRC). The aim of this study was to obtain proteomic expression profiles and identify serum markers for the early detection of CRC.

Methods

Proteomic profiles of serum samples collected from 35 healthy volunteers, 35 patients with advanced colorectal adenoma (ACA), and 40 patients with CRC were compared using Clinprot technology. Using enzyme-linked immunosorbent assays (ELISAs), 366 sera samples were additionally analyzed, and immunohistochemistry studies of 400 tissues were used to verify the expression of kininogen-1 and its value in the early detection of CRC.

Results

Predicting models were established among the three groups, and kininogen-1 was identified as a potential marker for CRC using Clinprot technology. ELISAs also detected significantly higher serum kininogen-1 levels in ACA and CRC patients compared to controls (P<0.05). Furthermore, the area under the receiver operating characteristic curve (AUC) for serum kininogen-1 in the diagnosis of ACA was 0.635 (P = 0.003), and for serum carcinoembryonic antigen (CEA) was 0.453 (P = 0.358). The sensitivity, specificity, and accuracy of serum kininogen-1 for diagnosing Duke’s stage A and B CRC was 70.13%, 65.88%, and 67.90%, respectively, whereas serum CEA was 38.96%, 85.88%, and 63.58%, respectively. Moreover, immunohistochemistry showed that expression of kininogen-1 was significantly higher in CRC and ACA tissues than in normal mucosa (48.39% vs. 15.58% vs. 0%, P<0.05).

Conclusions

These results suggest that Clinprot technology provides a useful tool for the diagnosis of CRC, and kininogen-1 is a potential serum biomarker for the early detection of advanced colorectal adenoma and CRC.     

Identification of proteins with altered expression in colorectal cancer by means of 2D-proteomics

Modern proteomic techniques make it possible to identify numerous changes in protein expression in tumors as compared to normal tissues. Although proteomics is currently widely used, identification of proteins differentially expressed in particular types of cancer remains a challenging task. The goal of our study was to detect novel protein markers of colorectal cancer using comparative proteomics of protein extracts obtained from primary tumors and adjacent normal tissues. Coloreetal cancer is nearly asymptomatic at the early stages, which calls for development of fast and sensitive methods for molecular diagnostics. Proteomes of 11 paired specimens of primary colorectal tumors and adjacent histologically normal tissues were studied using comparative 2D PAGE. Altogether, 16 proteins with altered expression levels were detected, including 13 proteins with increased levels and three proteins with decreased levels in tumor tissues. These proteins were identified using MALDI-TOF mass spectrometry. The proteins GPD1, RRBP1 (increased levels), HNRNPH1, and SERPINB6 (decreased levels) have been associated with colorectal cancer for the first time.     

MiR-26a在人垂体腺瘤组织及血清中表达的研究

目的：miRNA遍及生命体的发生、发育、分化和死亡的过程。它在肿瘤、心血管、糖尿病等多种疾病的各个阶段中起到调控癌基因作用。miRNA在垂体腺瘤中异常表达,且影响垂体腺瘤的增殖、侵袭及凋亡情况。本研究通过探讨miRNA家族中的miR-26a在垂体腺瘤组织及血清中的表达变化情况,为垂体瘤的早期诊断及疗效监测提供依据,以便更好的指导临床诊断及治疗工作。方法：收集哈尔滨医科大学附属第四医院微创神经外科手术切除并经病理证实的垂体腺瘤20例,取其组织及采集血清标本：年龄在20-74岁（平均50岁）,术前均未进行任何治疗。既往无内分泌疾病的正常死亡人的垂体组织及其血清标本20例作为对照组。采用实时定量聚合酶链式反应（Real-timePCR）方法分别检测垂体腺瘤病人和正常人组织及血清中的miRNA-26a的表达情况。用SPSSl3．0统计分析软件运用Mann—WhitneyU检验方法对数据进行统计学分析。结果：miRNA-26a在垂体腺瘤组织中的表达量为22．30,正常垂体组织中的表达量为23．38,垂体腺瘤患者血清中miRNA-26a的表达表达量为25．04,正常对照组血清中的表达量为24．95,垂体腺瘤组织中的表达较正常垂体组织中的表达明显升高（P〈0．05）,垂体腺瘤患者血清与正常人血清中miRNA-26a的表达无明显差异（P〉0．05）。结论：垂体腺瘤组织中miRNA-26a的高表达与血清学检测miRNA-26a的正常表达,为预防脑垂体腺瘤的发生和发展提供了重要的临床诊断依据。     

Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence

There is strong epidemiological and laboratory evidence that vitamin D may be protective against colorectal neoplasia. Therefore, we sought to assess the relationship between serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence in our ursodeoxycholic acid trial. A total of 568 participants were randomly selected for analysis of serum 25(OH)D levels. The range of total 25(OH)D was 5.5-66.1 ng/ml, with a median of 25.6 ng/ml. After categorizing 25(OH)D levels into tertiles based on the population distribution, the adjusted odds ratios (95% CI) for adenoma recurrence in the second and third tertiles were 0.88 (0.56-1.39) and 0.78 (0.49-1.24), respectively. The association between serum 25(OH)D and adenoma recurrence appeared to be stronger among women than men. As compared to those below the median value, women with serum 25(OH)D levels above the median had an OR (95% CI) of 0.59 (0.30-1.16); the corresponding OR (95% CI) for men was 0.95 (0.60-1.49). Analyses by dietary vitamin D intake revealed no statistically significant associations. In summary, the results of this study show a moderate, nonsignificant inverse association between serum 25(OH)D levels and reduced risk for colorectal adenoma recurrence, particularly among women.     

Clinical Significance of Frizzled Homolog 3 Protein in Colorectal Cancer Patients

Frizzled homolog 3 receptor was up-regulated in several gastrointestinal cancers such as esophageal and gastric cancers. Moreover, frizzled homolog 3 has recently reported to be expressed in colorectal adenoma specimens. In the present study, we investigated the clinical significance of frizzled homolog 3 protein in colorectal cancer patients. Using immunocytochemical staining, frizzled homolog 3 expression was examined in 186 colorectal cancer specimens, 79 colorectal adenoma specimens, 133 colorectal polyp specimens, 127 colorectal cancer specimens with lymph node and/or distant metastasis, 310 specimens of various non-colorectal cancer metastatic carcinomas and 40 specimens with simultaneous occurrence of colorectal cancer, colorectal adenoma and colorectal polyp. Statistical analysis was used to correlate frizzled homolog 3 protein expression to the clinicohistopathological factors, recurrence/metastasis and survival after follow-up for 42 months in colorectal cancer patients. Frizzled homolog 3 protein was expressed in 100% colorectal cancer specimens, 89% colorectal adenoma specimens, 75% colorectal polyp specimens and 69% normal colorectal epithelial tissues. Moreover, frizzled homolog 3 immunocytochemical scores were highly correlated with colorectal cancer progression. Furthermore, frizzled homolog 3 was expressed in a comparatively lower percentage of metastatic hepatocellular carcinoma and metastatic renal clear cell carcinoma with focal and very weak staining than other metastatic tumor types. On the other hand, the frizzled homolog 3 immunocytochemical scores of colorectal adenomas with synchronous colorectal carcinomas were significantly higher than those of pure colorectal adenomas. Statistical analysis showed that frizzled homolog 3 immunocytochemical scores were associated with Dukes stage and lymph node status. Finally, stratified groups of colorectal cancer patients had significant differences in their recurrence/metastasis and survival. In conclusion, the present large-scale study has clearly showed that frizzled homolog 3 protein can generate clinically important information for colorectal cancer patients.     

Proteomic profiling of urine for the detection of colon cancer

Background

Colorectal cancer is the second most common cause of cancer related death in the developed world. To date, no blood or stool biomarkers with both high sensitivity and specificity for potentially curable early stage disease have been validated for clinical use. SELDI and MALDI profiling are being used increasingly to search for biomarkers in both blood and urine. Both techniques provide information predominantly on the low molecular weight proteome (<15 kDa). There have been several reports that colorectal cancer is associated with changes in the serum proteome that are detectable by SELDI and we hypothesised that proteomic changes would also be detectable in urine.

Results

We collected urine from 67 patients with colorectal cancer and 72 non-cancer control subjects, diluted to a constant protein concentration and generated MALDI and SELDI spectra. The intensities of 19 peaks differed significantly between cancer and non-cancer patients by both t-tests and after adjusting for confounders using multiple linear regressions. Logistic regression classifiers based on peak intensities identified colorectal cancer with up to 78% sensitivity at 87% specificity. We identified and independently quantified 3 of the discriminatory peaks using synthetic stable isotope peptides (an 1885 Da fragment of fibrinogen and hepcidin-20) or ELISA (β2-microglobulin).

Conclusion

Changes in the urine proteome may aid in the early detection of colorectal cancer.     

Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling

Although colorectal cancer is one of the best-characterized tumors with regard to the multistep progression, it remains one of the most frequent and deadly neoplasms. For a better understanding of the molecular mechanisms behind the process of tumorigenesis and tumor progression, changes in protein expression between microdissected normal and tumorous colonic epithelium were analyzed. Cryostat sections from colorectal tumors, adenoma tissue, and adjacent normal mucosa were laser-microdissected and analyzed using ProteinChip Arrays. The derived MS profiles exhibited numerous statistical differences. One peak showing significantly high expression in the tumor was purified by reverse-phase chromatography and SDS-PAGE. The protein band of interest was passively eluted from the gel and identified as heat shock protein 10 (HSP 10) by tryptic digestion, peptide mapping, and MS/MS analysis. This tumor marker was further characterized by immunohistochemistry. Analysis of HSP 10-positive tissue by ProteinChip technology confirmed the identity of this protein. This work demonstrates that biomarker in colorectal cancer can be detected, identified, and assessed by a proteomic approach comprising tissue microdissection, protein profiling, and immunological techniques. In our experience, histological defined microdissected tissue areas should be used to identify proteins that might be responsible for tumorigenesis.